McDermott, D. F., Rini, B. I., Motzer, R. J., Tannir, N. M., Escudier, B., Kollmannsberger, C. K., … Powles, T. (2018). Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. In Ann Oncol (Vol. 29 Suppl 8, p. viii309). England. https://doi.org/10.1093/annonc/mdy283.083

McDermott, D. F., B. I. Rini, R. J. Motzer, N. M. Tannir, B. Escudier, C. K. Kollmannsberger, H. J. Hammers, et al. “Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis.” In Ann Oncol, 29 Suppl 8:viii309, 2018. https://doi.org/10.1093/annonc/mdy283.083.

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, et al. Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. In: Ann Oncol. 2018. p. viii309.

McDermott, D. F., et al. “Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis.” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii309. Pubmed, doi:10.1093/annonc/mdy283.083.

McDermott DF, Rini BI, Motzer RJ, Tannir NM, Escudier B, Kollmannsberger CK, Hammers HJ, Porta C, George S, Donskov F, Gurney HP, Grimm M-O, Harrison M, Hutson TE, Doan J, Yang S, Rao S, Mekan S, Ambavane A, Powles T. Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. Ann Oncol. 2018. p. viii309.